BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI)
CUSIP: 09075P105
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.001
- Shares outstanding
- 26,011,000
- Total 13F shares
- 9,738,748
- Share change
- +237,792
- Total reported value
- $12,466,903
- Put/Call ratio
- 204%
- Price per share
- $1.28
- Number of holders
- 71
- Value change
- -$1,711,528
- Number of buys
- 41
- Number of sells
- 41
Quarterly Holders Quick Answers
What is CUSIP 09075P105?
CUSIP 09075P105 identifies BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 09075P105:
Top shareholders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Rashmi Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,554,945
|
$187,267,747 | — | 03 Apr 2023 | |
| Vipin Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,554,945
|
$187,267,747 | — | 03 Apr 2023 | |
| Indu R. Gupta |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,550,396
|
$187,168,169 | — | 03 Apr 2023 | |
| Tarun K. Gupta |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,550,396
|
$187,168,169 | — | 03 Apr 2023 | |
| Suganthi Balasubramanian |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,547,750
|
$187,110,248 | — | 03 Apr 2023 | |
| Anita Jain |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,547,300
|
$187,100,398 | — | 03 Apr 2023 | |
| Diwakar Jain |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,547,300
|
$187,100,398 | — | 03 Apr 2023 | |
| Krishnan Nandabalan |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
8,840,750
mixed-class rows
|
$187,088,358 | — | 06 Apr 2023 | |
| Akrati Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Alka Sood |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Anesha Agarwal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Bina Jatin Patel |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| BioXcel Holdings, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 25 Jun 2021 | |
| BioXcel LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 25 Jun 2021 | |
| Jatin Markand Patel |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Krunal Dilip Patel |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Marshal D. Gibson |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Michael James Aiello |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| Pardeep Kumar Sood |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,546,750
|
$187,088,358 | — | 03 Apr 2023 | |
| FMR LLC |
13F
|
Company |
9.6%
|
2,494,116
|
$7,033,407 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
5.1%
|
1,328,061
|
$3,745,132 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.2%
|
1,099,375
|
$3,100,237 | — | 31 Mar 2024 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
2.2%
|
579,164
|
$1,633,243 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
464,908
|
$1,311,041 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
457,920
|
$1,291,484 | — | 31 Mar 2024 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.4%
|
370,973
|
$1,046,144 | — | 31 Mar 2024 | |
| Beacon Pointe Advisors, LLC |
13F
|
Company |
1.2%
|
301,735
|
$850,893 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.85%
|
222,299
|
$626,883 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.81%
|
211,602
|
$596,717 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.73%
|
190,970
|
$538,535 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.57%
|
147,157
|
$414,983 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.47%
|
123,086
|
$347,103 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.47%
|
123,077
|
$347,077 | — | 31 Mar 2024 | |
| Castleview Partners, LLC |
13F
|
Company |
0.37%
|
97,279
|
$274,326 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.35%
|
90,190
|
$254,336 | — | 31 Mar 2024 | |
| Pennant Investors, LP |
13F
|
Company |
0.32%
|
83,900
|
$236,598 | — | 31 Mar 2024 | |
| TOCQUEVILLE ASSET MANAGEMENT L.P. |
13F
|
Company |
0.19%
|
48,250
|
$136,065 | — | 31 Mar 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.18%
|
47,907
|
$135,098 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.18%
|
47,368
|
$133,578 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.17%
|
45,124
|
$127,250 | — | 31 Mar 2024 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.16%
|
42,108
|
$120,008 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.16%
|
40,643
|
$114,613 | — | 31 Mar 2024 | |
| THRIVENT FINANCIAL FOR LUTHERANS |
13F
|
Company |
0.15%
|
40,000
|
$113,000 | — | 31 Mar 2024 | |
| Cambridge Investment Research Advisors, Inc. |
13F
|
Company |
0.15%
|
38,050
|
$107,000 | — | 31 Mar 2024 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.14%
|
37,402
|
$105,474 | — | 31 Mar 2024 | |
| DAVENPORT & Co LLC |
13F
|
Company |
0.13%
|
34,385
|
$96,966 | — | 31 Mar 2024 | |
| XTX Topco Ltd |
13F
|
Company |
0.12%
|
31,212
|
$88,018 | — | 31 Mar 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.12%
|
29,990
|
$84,572 | — | 31 Mar 2024 | |
| Atom Investors LP |
13F
|
Company |
0.11%
|
29,816
|
$84,081 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.11%
|
29,685
|
$83,703 | — | 31 Mar 2024 |
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) as of Q2 2024
As of 30 Jun 2024,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) was held by
71 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,738,748 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, FMR LLC, VANGUARD GROUP INC, BlackRock Inc., BNP PARIBAS FINANCIAL MARKETS, GEODE CAPITAL MANAGEMENT, LLC, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, NORTHERN TRUST CORP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and WELLS FARGO & COMPANY/MN.
This page lists
72
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
71
Q2 2024 holders
71
Holder diff
0
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.